Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B

By sjmartinez • April 2, 2024

Gebremariam T, Alkhazraji S, Gu Y, Najvar LK, Borroto-Esoda K, Patterson TF, Filler SG, Wiederhold NP, Ibrahim AS. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. Antimicrob Agents Chemother. 2024 Apr 1:e0154523. doi: 10.1128/aac.01545-23. Epub ahead of print. PMID: 38557112.

Tags: combination therapy, Harbor UCLA, Ibrexafungerp, infection model, Infectious Diseases, liposomal amphotericin B, mouse, mucor, mucormycosis, posaconazole, Publications, Rhizopus

Related Posts

A rare case of May-Thurner syndrome due to external compression of the right and left common iliac veins

Schwarzman L, Aguilar J, Megowan N. A rare case of May-Thurner syndrome due to external compression of the right and left common iliac veins. J[...]

Advancing Equitable Kidney Care through Population Health Approaches in Los Angeles County’s Safety Net System

Kalantar-Zadeh K, Raff EA, Chong CC, Yang JK, Le TK, Barba LM, Pham PC, Dhamija R, Ghaffari A, Khine A, Patel N, Nicholas SB, Sim[...]

Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus: International Results from Peritoneal Dialysis Outcomes and Practice Patterns Study

Tennankore KK, McCullough K, Bieber B, Cho Y, Johnson DW, Kanjanabuch T, Kawanishi H, Kim YL, Lambie M, Rigatto C, Shen J, Schreiber M, Perl[...]